

30th April 2024

LEADERSHIP TRANSITION AT GENETIC SIGNATURES

Genetic Signatures Limited (ASX:GSS), an Australian-based, global molecular diagnostics company (**Genetic Signatures** or the **Company**) today announces that Dr. John Melki has stepped down from his role as CEO of the Company and from the Board of Directors. Dr. Melki has been an integral part of Genetic Signatures since joining in 2003. Under his leadership, the Company has achieved several significant milestones including the successful launch of various commercial products, its ASX listing, and positioned the Company for the prospective launch of its first FDA-approved product in the US.

The Board of Directors is grateful and appreciative of Dr. Melki's dedication and leadership during his tenure. "Dr. John Melki's departure from Genetic Signatures signifies the completion of a significant chapter in our Company's history." said Dr. Nick Samaras, Chairman of Genetic Signatures. "His scientific and executive leadership have been pivotal in enabling the Company to successfully transition from a research and development company to a commercial organisation. We sincerely thank Dr. Melki for this and wish him the very best in his future endeavours."

With the anticipated launch of the Company's first **3base**[®] product in the US expected later this year, the Board has initiated a search process to recruit its next CEO who will lead Genetic Signatures into its next phase of commercial growth. This will include a key focus on the significant commercial opportunities in the US market as well as expanding our existing customer base. Dr Neil Gunn, a highly experienced diagnostics executive and current Board member, is to assume the interim CEO position while we finalise the appointment of the new CEO.

Dr. Melki will act as an adviser to the CEO during this transition.

Genetic Signatures remains committed to its mission of providing innovative molecular diagnostic solutions and looks forward to continuing its growth trajectory under new leadership.

– ENDS –

Authorisation and Additional Information

This announcement was authorised by the Board of Directors of Genetic Signatures Limited.

For further information, visit www.geneticsignatures.com or email info@geneticsignatures.com.

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base**[®]. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen*[™] brand. Genetic Signatures' proprietary MDx **3base**[®] platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospitals and pathology laboratories undertaking infectious disease screening. Genetic Signatures is leveraging strong COVID-19 related sales of its *EasyScreen*[™] respiratory kits and the

growing interest in its gastroenteritis products to further commercialise its **3base**[®] technology to rapidly and cost effectively screen for a wide array of infectious pathogens including antibiotic resistant bacteria, sexually transmitted infections, meningitis and mosquito borne viral diseases.